跳至主要内容
临床试验/NCT02057523
NCT02057523终止4 期

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

University of Illinois at Chicago1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
2
试验地点
1
主要终点
50% Reduction in Proteinuria or Proteinuria < 150mg/Day

研究概览

简要总结

The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy.
  • Failed standard therapy (>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression

排除标准

  • 未提供

研究组 & 干预措施

Acthar

Experimental

Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.

干预措施: Acthar (Drug)

结局指标

主要结局

50% Reduction in Proteinuria or Proteinuria < 150mg/Day

时间窗: 6 months

次要结局

  • 25% Improvement in the MDRD eGFR(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sanjeev Akkina

Assistant Professor

University of Illinois at Chicago

研究点 (1)

Loading locations...

相似试验

Acthar as Rescue Therapy for Transplant... | 临床试验